National Heart, Lung, and Blood Institute; Notice of Closed Meeting, 70079-70080 [05-22933]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices
70079
FEE SCHEDULE JANUARY 1, 2006–SEPTEMBER 30, 2006
Vessel size
GRT 1
Extra Small ..................................................................................................................................................
Small ............................................................................................................................................................
Medium ........................................................................................................................................................
Large ............................................................................................................................................................
Extra Large ..................................................................................................................................................
1 Gross
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Notice of Approval of Supplemental
New Animal Drug Application;
Ivermectin and Praziquantel Paste
Food and Drug Administration,
HHS.
ACTION:
<3,001
3,001–15,000
15,001–30,000
30,001–60,000
>60,000
1,300
2,600
5,200
7,800
10,400
register tonnage in cubic feet, as shown in Lloyd’s Register of Shipping.
Inspections and reinspections involve the
same procedure, require the same amount of
time, and are therefore charged at the same
rate.
[FR Doc. 05–22967 Filed 11–18–05; 8:45 am]
AGENCY:
Fee
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice that it has approved a
supplemental new animal drug
application (NADA) filed by Merial, Ltd.
The NADA provides for oral use of an
ivermectin and praziquantel paste as an
over-the-counter product for the
treatment and control of various
parasitic conditions of horses. This
supplemental NADA reduces the
minimum age for administration from 5
months to 2 months of age.
FOR FURTHER INFORMATION CONTACT:
Melanie R. Berson, Center for Veterinary
Medicine (HFV–110), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301–827–7543, email: melanie.berson@fda.gov.
SUPPLEMENTARY INFORMATION: Merial,
Ltd., 3239 Satellite Blvd., bldg. 500,
Duluth, GA 30096–4640, filed a
supplement to NADA 141–214 for
ZIMECTERIN GOLD (ivermectin 1.55%/
praziquantel 7.75%) Paste, an over-thecounter product used for the oral
treatment and control of various
parasitic conditions of horses. This
supplemental NADA reduces the
minimum age for administration from 5
months to 2 months of age. In
accordance with section 512(i) of the
Federal Food, Drug, and Cosmetic Act
(the act) (21 U.S.C. 360b(i)) and part 514
(21 CFR part 514) in §§ 514.105(a) and
514.106(a), the Center for Veterinary
Medicine is providing notice that this
VerDate Aug<31>2005
15:51 Nov 18, 2005
Jkt 208001
supplemental NADA is approved as of
October 28, 2005. The basis of approval
is discussed in the freedom of
information summary.
In accordance with the freedom of
information provisions of 21 CFR part
20 and § 514.11(e)(2)(ii), a summary of
safety and effectiveness data and
information submitted to support
approval of this application may be seen
in the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852, between 9
a.m. and 4 p.m., Monday through
Friday.
FDA has determined under 21 CFR
25.33(d)(1) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
neither an environmental assessment
nor an environmental impact statement
is required.
Dated: November 7, 2005.
Steven D. Vaughn,
Director, Office of New Animal Drug
Evaluation, Center for Veterinary Medicine.
[FR Doc. 05–22941 Filed 11–18–05; 8:45 am]
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel, Gene Therapy
Clinical Trial.
Date: November 21, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Gateway Hotel Los Angeles
Airport, 6101 W Century Blvd., Los Angeles,
CA 90045.
Contact Person: Samuel Rawlings, PhD,
Chief, Scientific Review Branch, Division of
Extramural Research, National Eye Institute,
5635 Fishers Lane, Suite 1300, MSC 9300,
Bethesda, MD 20892–9300, 301–451–2020.
(Catalogue of Federal Domestic
Assistance Program No. 93.867, Vision
Research, National Institutes of Health,
HHS)
Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–22932 Filed 11–18–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4160–01–S
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
Board of Scientific Counselors, NHLBI.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual grant
applications conducted by the National
Heart, Lung, and Blood Institute,
including consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
National Eye Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00023
Fmt 4703
Sfmt 4703
Name of Committee: Board of Scientific
Counselors, NHLBI.
E:\FR\FM\21NON1.SGM
21NON1
70080
Federal Register / Vol. 70, No. 223 / Monday, November 21, 2005 / Notices
Date: December 14, 2005.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate the
Laboratory of Cell Biology, the Laboratory of
Molecular Cardiology, and the Laboratory of
Developmental Biology.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Robert S. Balaban, PhD,
Scientific Director, Division of Intramural
Research, National Institutes of Health,
NHLBI, Building 10, 4th Floor, Room 1581,
10 Center Drive, Bethesda, MD 20892, 301/
496–2116.
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/meetings/index.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93..837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–22933 Filed 11–18–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Contact Person: Mark Roltsch, PhD,
Scientific Review Administrator, Review
Branch, NHLBI, National Institutes of Health,
6701 Rockledge Drive, Room 7192, Bethesda,
MD 20892.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Review of Resource-Related Research Project
Applications (R24s).
Date: December 15, 2005.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Rockledge, 6701 Rockledge Drive, Bethesda,
MD 20814, (Telephone Conference Call).
Contact Person: Mark Roltsch, PhD,
Scientific Review Administrator, Review
Branch, NHLBI, National Institutes of Health,
6701 Rockledge Drive, Room 7192, Bethesda,
MD 20892.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–22934 Filed 11–18–05; 8:45 am]
BILLING CODE 4140–01–M
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
National Institutes of Health
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Review of Resource-Related Research Project
Applications (R24s).
Date: December 7, 2005.
Time: 3 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
VerDate Aug<31>2005
15:51 Nov 18, 2005
Jkt 208001
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Inherited
Disease Research Access Committee, CIDR.
Date: January 5, 2006.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00024
Fmt 4703
Sfmt 4703
Place: Hyatt Regency Bethesda, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Jerry Roberts, PhD,
Scientific Review Administrator, Scientific
Review Branch, National Institutes of Health,
Building 38A, Bethesda, MD 20892, 301–
402–0838.
(Catalogue of Federal Domestic Assistance
Program No. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–22929 Filed 11–18–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel; Mitochondrial
Disorder.
Date: December 9, 2005.
Time: 9 a.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Washington, Pennsylvania
Ave. at 15th Street, NW., Washington, DC
20004.
Contact Person: Norman Chang, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, NIH, 6100
Executive Blvd., Room 5B01, Bethesda, MD
20892, (301) 496–1485,
changn@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS)
E:\FR\FM\21NON1.SGM
21NON1
]]>Agencies
[Federal Register Volume 70, Number 223 (Monday, November 21, 2005)]
[Notices]
[Pages 70079-70080]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-22933]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood Institute; Notice of Closed
Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of
the Board of Scientific Counselors, NHLBI.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual grant applications conducted by the National Heart, Lung,
and Blood Institute, including consideration of personnel
qualifications and performance, and the competence of individual
investigators, the disclosure of which would constitute a clearly
unwarranted invasion of personal privacy.
Name of Committee: Board of Scientific Counselors, NHLBI.
[[Page 70080]]
Date: December 14, 2005.
Time: 8:30 a.m. to 4:30 p.m.
Agenda: To review and evaluate the Laboratory of Cell Biology,
the Laboratory of Molecular Cardiology, and the Laboratory of
Developmental Biology.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Robert S. Balaban, PhD, Scientific Director,
Division of Intramural Research, National Institutes of Health,
NHLBI, Building 10, 4th Floor, Room 1581, 10 Center Drive, Bethesda,
MD 20892, 301/496-2116.
Information is also available on the Institute's/Center's home
page: https://www.nhlbi.nih.gov/meetings/index.htm, where an agenda
and any additional information for the meeting will be posted when
available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.233,
National Center for Sleep Disorders Research; 93..837, Heart and
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839,
Blood Diseases and Resources Research, National Institutes of
Health, HHS)
Dated: November 14, 2005.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-22933 Filed 11-18-05; 8:45 am]
BILLING CODE 4140-01-M
